"Cell Adhesion Molecules" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
| Descriptor ID |
D015815
|
| MeSH Number(s) |
D12.776.395.550.200 D12.776.543.550.200 D23.050.301.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cell Adhesion Molecules".
Below are MeSH descriptors whose meaning is more specific than "Cell Adhesion Molecules".
This graph shows the total number of publications written about "Cell Adhesion Molecules" by people in this website by year, and whether "Cell Adhesion Molecules" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 5 | 9 |
| 1996 | 2 | 0 | 2 |
| 1997 | 3 | 1 | 4 |
| 1998 | 2 | 1 | 3 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 4 | 4 | 8 |
| 2004 | 3 | 1 | 4 |
| 2005 | 7 | 4 | 11 |
| 2006 | 6 | 1 | 7 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 3 | 4 | 7 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 4 | 7 |
| 2013 | 1 | 4 | 5 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 5 | 6 |
| 2018 | 2 | 4 | 6 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Adhesion Molecules" by people in Profiles.
-
Dachsous and Fat coordinately repress the Dachs-Dlish-Approximated complex to control growth. J Cell Biol. 2024 Dec 02; 223(12).
-
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719.
-
Prediction of the essential intermolecular contacts for side-binding of VASP on F-actin. Cytoskeleton (Hoboken). 2024 Aug; 81(8):382-392.
-
Structural insights into the formation of repulsive netrin guidance complexes. Sci Adv. 2024 Feb 16; 10(7):eadj8083.
-
TGF-ß Signaling Prevents MHC Class II-Expressing Lymphatic Endothelial Cells from Reactivating Human Allogenic Memory CD4+ T Cells. J Immunol. 2023 09 01; 211(5):782-790.
-
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist. 2022 03 11; 27(3):e223-e232.
-
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4).
-
Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation. Gastroenterology. 2022 02; 162(2):521-534.e8.
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882.
-
CRELD1 controls T cell homeostasis. Nat Immunol. 2020 12; 21(12):1480-1482.